Previous close | 21.96 |
Open | 21.96 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 21.96 - 21.96 |
52-week range | 17.86 - 22.72 |
Volume | |
Avg. volume | 68 |
Market cap | 27.227B |
Beta (5Y monthly) | 0.22 |
PE ratio (TTM) | 17.02 |
EPS (TTM) | 1.29 |
Earnings date | 09 May 2024 |
Forward dividend & yield | 0.31 (1.40%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | N/A |
RATINGEN, Germany, April 19, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Europe GmbH is pleased to announce the launch of EndoGel, a training model designed for performing Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM) procedures. This innovative simulator, available in two versions - EndoGel for ESD and EndoGel for ESD/POEM - represents a significant advance in endoscopic training. This simulator aims to improve the skills of endoscopy professionals across Europe
A total of 126 jobs are potentially set to go at the three North-east Fujifilm Diosynth Biotechnologies UK sites
mikoto Colonoscopy training simulator by R ZERO Inc. This portable training simulator offers multiple polyps, a realistic colon texture, four levels of difficulty and the recording of multiple procedure metrics. RATINGEN, Germany, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fujifilm Healthcare Europe GmbH has announced a strategic partnership with R Zero for the exclusive distribution of mikoto, a state-of-the-art endoscopy simulation technology, throughout Europe. This collaboration aims at providing tra